{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:52:27Z","timestamp":1770997947099,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.amjmed.2005.11.020","type":"journal-article","created":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T05:03:59Z","timestamp":1146632639000},"page":"448.e27-448.e36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Comparing Rates of Dyspepsia with Coxibs vs NSAID+PPI: A Meta-Analysis"],"prefix":"10.1016","volume":"119","author":[{"given":"Brennan M.R.","family":"Spiegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Farid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth S.","family":"Dulai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Gralnek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.11.020_bib1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.11.020_bib2","first-page":"2731","article-title":"The cost of COX inhibitors","volume":"27","author":"Marra","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjmed.2005.11.020_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/gast.2000.9561","article-title":"Nonsteroidal anti-inflammatory drug gastropathy","volume":"119","author":"Hawkey","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.11.020_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0950-3579(97)80011-8","article-title":"Economics of osteoarthritis","volume":"11","author":"March","year":"1997","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.amjmed.2005.11.020_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0269-2813.2004.01834.x","article-title":"Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy","volume":"19","author":"DuBois","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2005.11.020_bib6","first-page":"579","article-title":"A clinician\u2019s guide to the selection of NSAID therapy","volume":"27","author":"Fendrick","year":"2002","journal-title":"P&T"},{"key":"10.1016\/j.amjmed.2005.11.020_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.11.020_bib8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.11.020_bib9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.11.020_bib10","first-page":"A554","article-title":"Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a cox-2 specific inhibitor, compared with conventional NSAIDs","volume":"118","author":"Goldstein","year":"2001","journal-title":"Gastroenterology"},{"issue":"9435","key":"10.1016\/j.amjmed.2005.11.020_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.11.020_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/art.11192","article-title":"Meta-analysis of dyspepsia and nonsteroidal anti-inflammatory drugs","volume":"49","author":"Ofman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjmed.2005.11.020_bib13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0016-5085(98)70541-4","article-title":"American Gastroenterological Association medical position statement","volume":"114","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.11.020_bib14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-138-10-200305200-00007","article-title":"The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis","volume":"138","author":"Spiegel","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.11.020_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.21065","article-title":"Minimizing complications from nonsteroidal anti-inflammatory drugs","volume":"15","author":"Spiegel","year":"2005","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.amjmed.2005.11.020_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.amjmed.2005.11.020_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.amjmed.2005.11.020_bib18","series-title":"Systematic Reviews in Health Care","author":"Egger","year":"2001"},{"issue":"9","key":"10.1016\/j.amjmed.2005.11.020_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/41.9.1008","article-title":"Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis","volume":"41","author":"Bensen","year":"2002","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.amjmed.2005.11.020_bib20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","article-title":"Rofecoxib, a specific inhibitor of cyclooxygenase 2 with clinical efficacy comparable with that of diclofenac sodium","volume":"43","author":"Cannon","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.amjmed.2005.11.020_bib21","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","article-title":"A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis","volume":"160","author":"Day","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.amjmed.2005.11.020_bib22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","article-title":"Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9196","key":"10.1016\/j.amjmed.2005.11.020_bib23","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.amjmed.2005.11.020_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/030097402320318431","article-title":"A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis","volume":"31","author":"Geusens","year":"2002","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.amjmed.2005.11.020_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.amjmed.2005.11.020_bib26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","article-title":"Comparison of the effect of rofecoxib, (a cyclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.amjmed.2005.11.020_bib27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/gut.52.6.820","article-title":"Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.amjmed.2005.11.020_bib28","first-page":"1804","article-title":"Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis","volume":"31","author":"Hawkey","year":"2004","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.amjmed.2005.11.020_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/01.HYP.0000115921.55353.e0","article-title":"Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics","volume":"43","author":"Izhar","year":"2004","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.amjmed.2005.11.020_bib30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/147323000102900602","article-title":"Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip","volume":"29","author":"Kivitz","year":"2001","journal-title":"J Int Med Res"},{"issue":"6","key":"10.1016\/j.amjmed.2005.11.020_bib31","first-page":"530","article-title":"Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis","volume":"51","author":"Kivitz","year":"2002","journal-title":"J Fam Pract"},{"issue":"5","key":"10.1016\/j.amjmed.2005.11.020_bib32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1532-5415.2004.52201.x","article-title":"Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee","volume":"52","author":"Kivitz","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10.1016\/j.amjmed.2005.11.020_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2004.01956.x","article-title":"Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis","volume":"19","author":"Kivitz","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.amjmed.2005.11.020_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079902125000282","article-title":"Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis","volume":"18","author":"Leung","year":"2002","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.amjmed.2005.11.020_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/joca.2001.0510","article-title":"Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip","volume":"10","author":"Makarowski","year":"2002","journal-title":"Osteoarthritis Cartilage"},{"issue":"8","key":"10.1016\/j.amjmed.2005.11.020_bib36","first-page":"1623","article-title":"A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis","volume":"29","author":"Matsumoto","year":"2002","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.amjmed.2005.11.020_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/030097401750065265","article-title":"Celecoxib versus diclofenac in the management of osteoarthritis of the knee","volume":"30","author":"McKenna","year":"2001","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.amjmed.2005.11.020_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/030097402320817059","article-title":"Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration","volume":"31","author":"Myllykangas-Luosujarvi","year":"2002","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"10.1016\/j.amjmed.2005.11.020_bib39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/rheumatology\/keg359","article-title":"Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers","volume":"42","author":"Pavelka","year":"2003","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.amjmed.2005.11.020_bib40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archfami.9.10.1124","article-title":"Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs","volume":"9","author":"Saag","year":"2000","journal-title":"Arch Fam Med"},{"issue":"10","key":"10.1016\/j.amjmed.2005.11.020_bib41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00042737-200210000-00011","article-title":"Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis","volume":"14","author":"Sikes","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.amjmed.2005.11.020_bib42","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis; a randomized controlled trial","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amjmed.2005.11.020_bib43","first-page":"43","article-title":"Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study","volume":"30","author":"Bianchi Porro","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.amjmed.2005.11.020_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1590-8658(00)80821-X","article-title":"Efficacy of pantoprazole in the prevention of peptic ulcers, induced by nonsteroidal anti-inflammatory drugs","volume":"32","author":"Bianchi Porro","year":"2000","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.amjmed.2005.11.020_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2036.1998.00288.x","article-title":"Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users","volume":"12","author":"Cullen","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.amjmed.2005.11.020_bib46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/00365529609010347","article-title":"Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy","volume":"31","author":"Ekstrom","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"26","key":"10.1016\/j.amjmed.2005.11.020_bib47","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis","volume":"347","author":"Chan","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2005.11.020_bib48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1053\/j.gastro.2004.07.010","article-title":"Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients","volume":"127","author":"Chan","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.11.020_bib49","unstructured":"Center for Medicare and Medicaid Services. Available at: www.cms.hhs.gov\/statistics\/medpar. Accessed March 1, 2005."},{"key":"10.1016\/j.amjmed.2005.11.020_bib50","unstructured":"Arthritis Pain Guideline Panel. March, 2002. Guidelines for the management of pain in osteroarthritis, rheumatoid arthritis, and juvenile chronic arthritis. American Pain Society publication. Available at: www.ampainsoc.org. Accessed March 1, 2005"},{"issue":"2","key":"10.1016\/j.amjmed.2005.11.020_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.162.2.169","article-title":"Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs","volume":"162","author":"Graham","year":"2002","journal-title":"Arch Int Med"},{"issue":"11","key":"10.1016\/j.amjmed.2005.11.020_bib52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305011393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305011393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:42:56Z","timestamp":1757580176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305011393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0002934305011393"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.11.020","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing Rates of Dyspepsia with Coxibs vs NSAID+PPI: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}